Dose-dependent effect of thalidomide (Thal) on overall survival (OS) in relapsed and refractory multiple myeloma (MM).

被引：0
|
作者：
Neben, K
Moehler, TM
Benner, A
Kraemer, A
Ho, AD
Goldschmidt, H
机构：
[1] Univ Heidelberg, Dept Internal Med 5, Heidelberg, Germany
[2] German Canc Res Ctr, Cent Unit Biostat, D-6900 Heidelberg, Germany
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
690
引用
收藏
页码：163A / 163A
页数：1
相关论文
共 50 条
  • [1] Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma
    Neben, K
    Moehler, T
    Benner, A
    Kraemer, A
    Egerer, G
    Ho, AD
    Goldschmidt, H
    CLINICAL CANCER RESEARCH, 2002, 8 (11) : 3377 - 3382
  • [2] TP53 Mutations In Relapsed/Refractory Multiple Myeloma (MM) Treated with Thalidomide (Thal) or Thalidomide Combination Therapy.
    Westerman, David Alan
    Zapparoli, Giada
    Hewitt, Chelsee
    Lynch, Kevin
    Mileshkin, Linda
    Link, Emma
    Dobrovic, Alexander
    Prince, H. Miles
    BLOOD, 2010, 116 (21) : 1649 - 1650
  • [3] Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM).
    Lokhorst, Henk M.
    Laubach, Jacob
    Nahi, Hareth
    Plesner, Torben
    Gimsing, Peter
    Hansson, Markus
    Minnema, Monique
    Lassen, Ulrik Niels
    Krejcik, Jakub
    Ahmadi, Tahamtan
    Lisby, Steen
    Basse, Linda
    Brun, Nikolai C.
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] DOSE-DEPENDENT EFFICACY OF DARATUMUMAB (DARA) AS MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RR MM)
    Lokhorst, H.
    Laubach, J.
    Nahi, H.
    Plesner, T.
    Gimsing, P.
    Hansson, M.
    Minnema, M.
    Lassen, U.
    Krejcik, J.
    Ahmadi, T.
    Khan, I.
    Uhlar, C.
    Lisby, S.
    Basse, L.
    Brun, N.
    Richardson, P.
    HAEMATOLOGICA, 2014, 99 : 106 - 107
  • [5] Durable response to thalidomide in relapsed/refractory multiple myeloma (MM).
    Raza, SN
    Veksler, Y
    Sabir, T
    Li, ZJ
    Anderson, L
    Jagannath, S
    BLOOD, 2000, 96 (11) : 168A - 169A
  • [6] Velcade (Vel), Doxil® (Dox) and low-dose thalidomide (Thal) as salvage therapy for patients (pts) with relapsed/refractory multiple myeloma (MM).
    Chanan-Khan, AA
    Miller, K
    Srinivasan, S
    David, S
    McCarthy, P
    Alam, A
    Bernstein, ZP
    Czuczman, MS
    BLOOD, 2003, 102 (11) : 389B - 389B
  • [7] ASSOCIATION BETWEEN PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS WITH RELAPSED/REFRACTORY (RR) MULTIPLE MYELOMA (MM)
    Mastikhina, L.
    Cope, S.
    Marshall, T.
    Maciel, D.
    Mojebi, A.
    Karampampa, K.
    Dhanda, D.
    VALUE IN HEALTH, 2023, 26 (12) : S30 - S31
  • [8] Low dose thalidomide in patients with relapsed or refractory multiple myeloma
    Kees, M
    Dimou, G
    Sillaber, C
    Drach, J
    Ackermann, J
    Lechner, K
    Gisslinger, H
    LEUKEMIA & LYMPHOMA, 2003, 44 (11) : 1943 - 1946
  • [9] Melphalan, thalidomide and decadron (MTD) for refractory/relapsed multiple myeloma (MM).
    Srkalovic, G
    Karam, MA
    McLain, DA
    Hussein, MA
    BLOOD, 1999, 94 (10) : 314B - 315B
  • [10] A Predictive Model of Overall Survival (OS) for Patients with Relapsed/Refractory Multiple Myeloma (MM) Enrolling in Phase I Clinical Trials
    Nooka, Amy K.
    Muppidi, Samatha
    Harvey, R. Donald
    Kaufman, Jonathan L.
    Langston, Amelia
    Lewis, Colleen
    Boise, Lawrence H.
    Flowers, Christopher R.
    Lonial, Sagar
    BLOOD, 2011, 118 (21) : 1691 - 1691
12345